There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akcea Therapeutics (AKCAResearch Report), Abbott Labs (ABTResearch Report) and Jazz Pharmaceuticals (JAZZResearch Report) with bullish sentiments.

Akcea Therapeutics (AKCA)

In a report released yesterday, Jim Birchenough from Wells Fargo maintained a Buy rating on Akcea Therapeutics. The company’s shares closed last Monday at $17.64.

According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 21.4% and a 51.0% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Crispr Therapeutics AG, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akcea Therapeutics with a $40.50 average price target.

See today’s analyst top recommended stocks >>

Abbott Labs (ABT)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Labs yesterday. The company’s shares closed last Monday at $85.48, close to its 52-week high of $88.76.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 15.5% and a 71.6% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Edwards Lifesciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Labs with a $91.50 average price target.

Jazz Pharmaceuticals (JAZZ)

In a report released yesterday, Jacob Hughes from Wells Fargo maintained a Buy rating on Jazz Pharmaceuticals. The company’s shares closed last Monday at $149.46, close to its 52-week high of $153.03.

Hughes has an average return of 1.1% when recommending Jazz Pharmaceuticals.

According to TipRanks.com, Hughes is ranked #3772 out of 5727 analysts.

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $178.00, implying a 19.1% upside from current levels. In a report issued on December 2, Barclays also maintained a Buy rating on the stock with a $200.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.



Source link